Stockreport

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics, Inc.  (TCRX) 
PDF First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme pro [Read more]